Lawmakers query FDA on labeling rule

Share this article:

Eight House and Senate health overseers are challenging the FDA's use of limited resources to prepare a proposed rule on when medical product companies can make safety-related labeling changes without prior approval. In a letter to Andrew von Eschenbach they said the proposal was “apparently designed to shield…companies from liability for injuries sustained by American consumers as a result of unsafe products.”

Earlier, the FDA published the proposed rule in the Federal Register and said it was codifying “the agency's understanding that a CBE supplement is appropriate to amend the labeling for an approved product only to reflect newly acquired information, and to clarify that a CBE supplement may be used to add or strengthen a contraindication, warning, precaution, or adverse reaction only if there is sufficient evidence of a causal association with the approved product.”

In the letter, the members say the FDA “failed to provide any justification for expending its very limited resources on issuing this 26 page proposal that will serve only to deprive American consumers of critically important and timely information about the safety of their drugs and medical devices…The issuance of the proposed CBE rule is not an isolated case, but part of a pattern of actions in the administration's final months to permanently insulate the drug and device industry from liability.”

The letter takes issue with the assertion that the proposal codifies the agency's longstanding view on when a labeling change may be made. “To the contrary, the proposed changes would instead drastically limit the situations in which a manufacturer is permitted to make add or strengthen a contraindication, warning, precaution, or adverse reaction without waiting for FDA to approve such a change. Under FDA's proposal, a manufacturer would now be prohibited from adding or strengthening a contraindication, warning, precaution, or adverse reaction in the absence of FDA approval unless there is ‘evidence of a causal association.'”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: HealthSpot's teleconnected CEO

Headliner: HealthSpot's teleconnected CEO

Steve Cashman, Founder and CEO, HealthSpot

Recruitment: The New Breed

Recruitment: The New Breed

What do healthcare agencies really want when it comes to potential employees? The answer to that question is in a constant state of flux, as technologies, clients' changing demands and ...

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the September 2014 issue of MM&M, with all text, charts and pictures.